Biome Australia (BIO) H2 2026 earnings summary

Executive summary

• Achieved record sales revenue of $23.9 million in FY26, up 30% year-over-year, with a second consecutive year of net profit at $3.6 million (including a $2.4 million deferred tax asset recognition).

• EBITDA (excluding share-based payments) rose 115% to $2.0 million, and profit before tax reached $1.2 million.

• Domestic business was the primary driver, with over 100,000 units sold in June and strong market leadership in Australian pharmacy.

• International revenue grew 20% to $1.8 million, with expansion in Canada, Ireland, UK, and New Zealand.

• Strategic onshore manufacturing agreement signed to improve gross margin and supply chain resilience.

Financial highlights

• Revenue: $23,883,240 (FY26), up from $18,417,188 (FY25).

• Net profit after tax: $3,608,226 (FY26), up from $214,656 (FY25).

• EBITDA (excl. share-based payments): $2,000,296, up 115% year-over-year.

• Gross profit: $14,936,188, gross margin 62.1% (FY25: 61.1%).

• Operating cash inflow: $1,626,949, a $4.5 million turnaround from prior year.

• Cash at year-end: $3,551,175; undrawn credit facility: $3,100,000.

• Debt reduced by $1,005,413 to $1,900,000.

Outlook and guidance

• Vision 27 targets at least $75 million cumulative sales revenue across FY25–FY27; $42.3 million delivered in first two years.

• Onshore manufacturing transition expected to improve gross margin and working capital over next 18 months.

• International business positioned to scale, with new product launches and expanded distribution planned for FY27.